Use of liposome-associated bupivacaine in a cancer pain syndrome.
Bupivacaine 0.25% encapsulated by multilamellar liposomes was administered epidurally to a patient suffering pain associated with lung cancer and the effect compared with a plain bupivacaine solution of the same concentration. Complete analgesia was produced for 4 h with the plain solution and 11 h with the liposomal formulation. No motor blockade or haemodynamic instability was observed with the liposome-associated bupivacaine.
Lafont
N D
ND
Laboratory of Physiopathology, Free University of Brussels, Belgium.
Legros
F J
FJ
Boogaerts
J G
JG
D000368:Aged; D015360:Analgesia, Epidural / Q000379:methods*; D000779:Anesthetics, Local / Q000008:administration & dosage*; D002045:Bupivacaine / Q000008:administration & dosage*; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology; D013577:Syndrome
D000779:Anesthetics, Local; D004337:Drug Carriers; D008081:Liposomes; D002045:Bupivacaine